Skip Navigation

European Heart Journal 2001 22(15):1343-1352; doi:10.1053/euhj.2001.2729
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Grossman, E
Right arrow Articles by Goldbourt, U
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grossman, E
Right arrow Articles by Goldbourt, U
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Antihypertensive therapy and the risk of malignancies

E Grossmana, F.H Messerlib,f1 and U Goldbourtc,d

a Internal Medicine D, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
b Department of Internal Medicine, Section on Hypertensive Diseases, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, LA, U.S.A.
c The Neufeld Cardiac Institute, The Chaim Sheba Medical Center, Tel-Hashomer, Israel
d Division of Epidemiology and Preventive Medicine, Sackler School of Medicine, Tel-Aviv University, Israel

revised April 3, 2001; accepted April 4, 2001

Abstract

Aims To assess the relationship between antihypertensive therapy and malignancy.

Methods and Results A MEDLINE search for English-language articles published between January 1966 and August 1999 identified 29 prospective studies that reported cancer incidence or mortality and 28 case-control studies that reported specific drug use in cancer patients and controls. The association between rauwolfia derivatives and breast cancer was analysed in 5852 cases and 9776 controls, yielding an odds ratio (OR) of 1·25 (95% CI, 1·09–1·44). The association between diuretics and renal cell carcinoma was analysed in 4389 cases and 6566 controls, yielding a pooled OR of 1·54 (95% CI, 1·41–1·68). The association between atenolol and cancer death was analysed pooling three randomized controlled studies, including 1879 treated patients and 3078 non-treated patients, yielding a pooled OR of 1·36 (95% CI, 1·02–1·82); however, data from non-randomized studies did not confirm the latter. The association between calcium antagonists and malignancy was analysed pooling five randomized controlled studies, including 5451 treated patients and 5207 untreated ones, yielding a pooled OR of 0·78 (CI, 0·60–1·00). A meta-analysis of an additional five longitudinal studies, including 9087 treated patients and 15559 non-treated patients, yielded a pooled OR of 1·04 (CI, 0·91–1·19). The association between ACE inhibitors and malignancy was analysed pooling two randomized controlled trials involving 1585 treated patients and 1567 non-treated patients, yielding a pooled OR of 1·57 (95% CI, 0·97–2·57); however, non-randomized studies showed no association or a decreased risk for malignancy with ACE inhibitors.

Conclusions With the exception of diuretics and renal cell carcinoma, the association between antihypertensive drugs and malignancy was either low grade (rauwolfia), uncertain (atenolol), absent (ACE inhibitors), or absent with a yet to be investigated inverse association (calcium antagonists). Ongoing long-term prospective studies with cardiovascular drugs should carefully monitor the risk of malignancy.

Key Words: Antihypertensive therapy and malignancy, diuretics, renal cell carcinoma, calcium antagonists, ACE inhibitors

f1 Correspondence: Franz H. Messerli, MD, Ochsner Clinic, 1514 Jefferson Highway, New Orleans, LA 70121, U.S.A.

References

  1. Br Med J (Clin Res Ed). 1985;291:97–104[Medline]
  2. Lancet. 1980;1:1261–1267[Medline]
  3. Br Med J. 1992;304:405–412[ISI][Medline]
  4. Staessen J, Bulpitt C, Clement D. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. Br Med J. 1989;298:1552–1556[ISI][Medline]
  5. JAMA. 1991;265:3255–3264[Abstract]
  6. Williams RR, Feinleib M, Connor RJ, Stegens NL. Case-control study of antihypertensive and diuretic use by women with malignant and benign breast lesions detected in a mammography screening program. J Natl Cancer Inst. 1978;61:327–335[ISI][Medline]
  7. Fraser GE, Phillips RL, Beeson WL. Hypertension, antihypertensive medication and risk of renal carcinoma in California Seventh-Day Adventists. Int J Epidemiol. 1990;19:832–838[Abstract/Free Full Text]
  8. Grove JS, Nomura A, Severson RK, Stemmermann GN. The association of blood pressure with cancer incidence in a prospective study. Am J Epidemiol. 1991;134:942–947[Abstract/Free Full Text]
  9. McCredie M, Stewart JH. Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control. 1992;3:323–331[CrossRef][ISI][Medline]
  10. Suadicani P, Hein HO, Gyntelberg F. Is the use of antihypertensives and sedatives a major risk factor for colorectal cancer? Scand J Gastroenterol. 1993;28:475–481[ISI][Medline]
  11. McLaughlin JK, Chow WH, Mandel JS. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer. 1995;63:216–221[ISI][Medline]
  12. Chow WH, McLaughlin JK, Mandel JS, Wacholder S, Niwa S, Fraumeni JF Jr. Risk of renal cell cancer in relation to diuretics, antihypertensive drugs, and hypertension. Cancer Epidemiol Biomarkers Prev. 1995;4:327–331[Abstract]
  13. Peeters PH, van Noord PA, Hoes AW, Grobbee DE. Hypertension, antihypertensive drugs, and mortality from cancer among women. J Hypertens. 1998;16:941–947[CrossRef][ISI][Medline]
  14. Rosenberg L, Rao RS, Palmer JR. Calcium channel blockers and the risk of cancer. JAMA. 1998;279:1000–1004[Abstract/Free Full Text]
  15. Lancet. 1974;2:669–671[Medline]
  16. Mellemgaard A, Moller H, Olsen JH. Diuretics may increase risk of renal cell carcinoma. Cancer Causes Control. 1992;3:309–312[CrossRef][ISI][Medline]
  17. Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control. 1993;4:101–110[CrossRef][ISI][Medline]
  18. Mellemgaard A, Niwa S, Mehl ES, Engholm G, McLaughlin JK, Olsen JH. Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol. 1994;23:923–930[Abstract/Free Full Text]
  19. Finkle WD, McLaughlin JK, Rasgon SA, Yeoh HH, Low JE. Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control. 1993;4:555–558[CrossRef][ISI][Medline]
  20. Hiatt RA, Tolan K, Quesenberry CP Jr. Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). Cancer Causes Control. 1994;5:319–325[CrossRef][ISI][Medline]
  21. Weinmann S, Glass AG, Weiss NS, Psaty BM, Siscovick DS, White E. Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol. 1994;140:792–804[Abstract/Free Full Text]
  22. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens. 1996;9:695–699[CrossRef][ISI][Medline]
  23. Pahor M, Guralnik JM, Ferrucci L. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348:493–497[CrossRef][ISI][Medline]
  24. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer. 1997;80:1438–1447[CrossRef][ISI][Medline]
  25. Armstrong B, Stevens N, Doll R. Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women. Lancet. 1974;2:672–675[ISI][Medline]
  26. Heinonen OP, Shapiro S, Tuominen L, Turunen MI. Reserpine use in relation to breast cancer. Lancet. 1974;2:675–677[ISI][Medline]
  27. Mack TM, Henderson BE, Gerkins VR, Arthur M, Baptista J, Pike MC. Reserpine and breast cancer in a retirement community. N Engl J Med. 1975;292:1366–1371[Abstract]
  28. O'Fallon WM, Labarthe DR, Kurland LT. Rauwolfia derivatives and breast cancer. A case/control study in Olmsted County, Minnesota. Lancet. 1975;2:292–296[CrossRef][Medline]
  29. Laska EM, Siegel C, Meisner M, Fischer S, Wanderling J. Matched-pairs study of reserpine use and breast cancer. Lancet. 1975;2:296–300[CrossRef][ISI][Medline]
  30. Armstrong B, Skegg D, White G, Doll R. Rauwolfia derivatives and breast cancer in hypertensive women. Lancet. 1976;2:8–12[CrossRef][ISI][Medline]
  31. Lilienfeld AM, Chang L, Thomas DB, Levin ML. Rauwolfia derivatives and breast cancer. Johns Hopkins Med J. 1976;139:41–50[ISI][Medline]
  32. Aromaa A, Hakama M, Hakulinen T, Saxen E, Teppo L, Ida lan-Heikkila J. Breast cancer and use of rauwolfia and other antihypertensive agents in hypertensive patients: a nationwide case-control study in Finland. Int J Cancer. 1976;18:727–738[ISI][Medline]
  33. Kewitz H, Jesdinsky HJ, Schroter PM, Lindtner E. Reserpine and breast cancer in women in Germany. Eur J Clin Pharmacol. 1977;11:79–83[CrossRef][ISI][Medline]
  34. Christopher LJ, Crooks J, Davidson JF. A multicentre study of rauwolfia derivates and breast cancer. Eur J Clin Pharmacol. 1977;11:409–417[CrossRef][ISI][Medline]
  35. Kodlin D, McCarthy N. Reserpine and breast cancer. Cancer. 1978;41:761–768[CrossRef][ISI][Medline]
  36. Shapiro S, Parsells JL, Rosenberg L, Kaufman DW, Stolley PD, Schottenfeld D. Risk of breast cancer in relation to the use of rauwolfia alkaloids. Eur J Clin Pharmacol. 1984;26:143–146[CrossRef][ISI][Medline]
  37. Labarthe DR, O'Fallon WM. Reserpine and breast cancer. A community-based longitudinal study of 2,000 hypertensive women. JAMA. 1980;243:2304–2310[Abstract]
  38. Curb JD, Hardy RJ, Labarthe DR, Borhani NO, Taylor JO. Reserpine and breast cancer in the Hypertension Detection and Follow-Up Program. Hypertension. 1982;4:307–311[Abstract/Free Full Text]
  39. Friedman GD. Rauwolfia and breast cancer: no relation found in long term users age fifty and over. J Chronic Dis. 1983;36:367–370[CrossRef][ISI][Medline]
  40. Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst. 1986;77:351–356[ISI][Medline]
  41. Shapiro JA, Williams MA, Weiss NS, Stergachis A, LaCroix AZ, Barlow WE. Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol. 1999;149:521–530[Abstract/Free Full Text]
  42. Prineas RJ, Folsom AR, Zhang ZM, Sellers TA, Potter J. Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology. 1997;8:31–36[ISI][Medline]
  43. Heath CW Jr, Lally CA, Calle EE, McLaughlin JK, Thun MJ. Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am J Epidemiol. 1997;145:607–613[Abstract/Free Full Text]
  44. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed). 1986;293:1145–1151[Medline]
  45. BMJ. 1998;317:713–720[Abstract/Free Full Text]
  46. Hole DJ, Hawthorne VM, Isles CG. Incidence of and mortality from cancer in hypertensive patients. Br Med J. 1993;306:609–611[ISI][Medline]
  47. Fletcher AE, Beevers DG, Bulpitt CJ. Cancer mortality and atenolol treatment. BMJ. 1993;306:622–623[ISI][Medline]
  48. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet. 1997;349:525–528[CrossRef][ISI][Medline]
  49. Borhani, NO, Mercuri, M, Borhani, PA, Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS), A randomized controlled trial, JAMA, 1996, 276, 785, 91
  50. Packer M, O'Connor CM, Ghali JK. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107–1114[Abstract/Free Full Text]
  51. Gong L, Zhang W, Zhu Y. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 1996;14:1237–1245[ISI][Medline]
  52. Staessen JA, Fagard R, Thijs L. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757–764[CrossRef][ISI][Medline]
  53. Liu L, Wang JG, Gong L. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998;16:1823–1829[CrossRef][ISI][Medline]
  54. Jonas M, Goldbourt U, Boyko V, Mandelzweig L, Behar S, Reicher-Reiss H. Nifedipine and cancer mortality: ten-year follow-up of 2607 patients after acute myocardial infarction. Cardiovasc Drugs Ther. 1998;12:177–181[CrossRef][ISI][Medline]
  55. Hole DJ, Gillis CR, McCallum IR. Cancer risk of hypertensive patients taking calcium antagonists. J Hypertens. 1998;16:119–124[CrossRef][ISI][Medline]
  56. Braun S, Boyko V, Behar S. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. J Am Coll Cardiol. 1998;31:804–808[Abstract/Free Full Text]
  57. Olsen JH, Toft Sorensen HT, Friis S. Cancer risk in users of calcium channel blockers. Hypertension. 1997;29:1091–1094[Abstract/Free Full Text]
  58. N Engl J Med. 1992;327:685–691[Abstract]
  59. Maschio G, Alberti D, Janin G. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939–945[Abstract/Free Full Text]
  60. Lever AF, Hole DJ, Gillis CR. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352:179–184[CrossRef][ISI][Medline]
  61. Kaufman DW, Kelly JP, Rosenberg L, Stolley PD, Schottenfeld D, Shapiro S. Hydralazine and breast cancer. J Natl Cancer Inst. 1987;78:243–246[ISI][Medline]
  62. Kaufman DW, Kelly JP, Rosenberg L, Stolley PD, Warshauer ME, Shapiro S. Hydralazine use in relation to cancers of the lung, colon, and rectum. Eur J Clin Pharmacol. 1989;36:259–264[CrossRef][ISI][Medline]
  63. Gahlinger, PM, Abramson, JH, CASECONT and COMBINE in Programs for Epidemiologic Analysis (PEPI) version 2, 1995, 33, 41
  64. Fleiss JL. Statistical Methods for Rates and Proportions. New York: John Wiley & Sons; 1991.
  65. Brandenburg NA, Backstrom JT, Hinkle RL. Calcium channel blockers and cancer: the evidence against an association [letter]. Am J Hypertens. 1996;9:1049–1050[CrossRef][ISI][Medline]
  66. Weisenburger DD. Immunoblastic lymphadenopathy associated with methyldopa therapy: a case report. Cancer. 1978;42:2322–2327[CrossRef][ISI][Medline]
  67. Broden G, Bengtsson L. Biliary carcinoma associated with methyldopa therapy. Acta Chir Scand Suppl. 1980;500:7–12[Medline]
  68. Strom BL, Hibberd PL, Stolley PD. No evidence of association between methyldopa and biliary carcinoma. Int J Epidemiol. 1985;14:86–90[Abstract/Free Full Text]
  69. Dyer AR, Stamler J, Berkson DM, Lindberg HA, Stevens E. High blood-pressure: a risk factor for cancer mortality? Lancet. 1975;1:1051–1056[ISI][Medline]
  70. Newball HH, Byar DP. Does reserpine increase prolactin and exacerbate cancer of prostate? Case control study. Urology. 1973;2:525–529[CrossRef][Medline]
  71. Byar DP, Blackard CE. Reserpine and prostatic cancer (letters). Urology. 1975;5:158–159[Medline]
  72. Lijinsky W, Reuber MD. Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats. Toxicol Ind Health. 1987;3:413–422[ISI][Medline]
  73. Loffing J, Loffing-Cueni D, Hegyi I. Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int. 1996;50:1180–1190[ISI][Medline]
  74. Zavanella T, Radaelli G, Girotti P. Evaluation of the tumor-promoting activity of two beta-adrenoreceptor blocking agents, propranolol and atenolol, in liver of Fischer 344 rats. Carcinogenesis. 1994;15:2531–2539[Abstract/Free Full Text]
  75. Ioannides C, Okine L, Parke DV. Effects of beta-adrenoceptor antagonists on the hepatic mixed-function oxygenases in the rat [proceedings]. Br J Pharmacol. 1979;67:451P–452P[Medline]
  76. Boyd H, Martin TJ. The effect of propranolol on induction of rat liver tumors by a chemical carcinogen. Mol Pharmacol. 1977;13:576–578[Abstract/Free Full Text]
  77. Gurkalo VK, Zabezhinski MA. On participation of the autonomic nervous system in the mechanisms of chemical carcinogenesis. Neoplasma. 1982;29:301–307[ISI][Medline]
  78. Messerli FH, Grossman E. Antihypertensive agents and the risk of cancer [letter]. JAMA. 1998;280:600[Free Full Text]
  79. Mickisch GH, Kossig J, Keilhauer G, Schlick E, Tschada RK, Alken PM. Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res. 1990;50:3670–3674[Abstract/Free Full Text]
  80. al-Shabanah OA, Osman AM, al-Harbi MM, al-Bekairi AM, al-Gharably NM, Aziz SA. Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in Ehrlich ascites carcinoma cells. Chemotherapy. 1995;41:368–377[ISI][Medline]
  81. al-Gharably NM, Osman AM, al-Shabanah OA, al-Bekairi AM, al-Harbi MM. Potentiation of doxorubicin cytotoxicity by the calcium channel blocker verapamil in Ehrlich ascites cells. Chemotherapy. 1993;39:410–415[ISI][Medline]
  82. Kunert-Radek J, Stepien H, Radek A, Lyson K, Pawlikowski M. Inhibitory effect of calcium channel blockers on proliferation of human glioma cells in vitro. Acta Neurol Scand. 1989;79:166–169[ISI][Medline]
  83. Lee YS, Sayeed MM, Wurster RD. Intracellular Ca2+ mediates the cytotoxicity induced by bepridil and benzamil in human brain tumor cells. Cancer Lett. 1995;88:87–91[CrossRef][ISI][Medline]
  84. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer. 1993;72:3553–3563[CrossRef][ISI][Medline]
  85. Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res. 1992;52:2413–2418[Abstract/Free Full Text]
  86. Rasmussen H, Barrett PQ. Calcium messenger system: an integrated view. Physiol Rev. 1984;64:938–984[Free Full Text]
  87. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet. 1990;335:1109–1113[CrossRef][ISI][Medline]
  88. Reddy MK, Baskaran K, Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med. 1995;210:221–226[Abstract]
  89. Small W Jr, Molteni A, Kim YT, Taylor JM, Chen Z, Ward WF. Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res Treat. 1997;44:217–224[CrossRef][ISI][Medline]
  90. Chen L, Re RN, Prakash O, Mondal D. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med. 1991;196:280–283[Abstract]
  91. Ward WF, Molteni A, Ts'ao C, Hinz JM. The effect of Captopril on benign and malignant reactions in irradiated rat skin. Br J Radiol. 1990;63:349–354[Abstract]
  92. Ward WF, Molteni A, Kim YT, Ts'ao CH, Taylor JM. Captopril inhibits mitosis and growth of diethylnitrosamine-induced preneoplastic hepatic foci in F344 rats. FASEB J. 1992;5:A
  93. Bastiaens MT, Zwan NV, Verschueren GL, Stoof TJ, Nieboer C. Three cases of pemphigus vegetans: induction by enalapril—association with internal malignancy. Int J Dermatol. 1994;33:168–171[ISI][Medline]
  94. Larbre JP, Nicolas JF, Collet P, Larbre B, Llorca G. Kaposi's sarcoma in a patient with rheumatoid arthritis possible responsibility of captopril in the development of lesions. J Rheumatol. 1991;18:476–477[ISI][Medline]
  95. Furness PN, Goodfield MJ, MacLennan KA, Stevens A, Millard LG. Severe cutaneous reactions to captopril and enalapril; histological study and comparison with early mycosis fungoides. J Clin Pathol. 1986;39:902–907[Abstract/Free Full Text]
  96. Puppin D Jr, Rybojad M, de la Chapelle C, Morel P. Kaposi's sarcoma associated with captopril [letter]. Lancet. 1990;336:1251–1252[ISI][Medline]
  97. Carroll J, Thaler M, Grossman E, Alder A, Trau H, Rosenthal T. Generalized pustular eruption associated with converting enzyme inhibitor therapy. Cutis. 1995;56:276–278[ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J EpidemiolHome page
V. W. Setiawan, D. O. Stram, A. M. Y. Nomura, L. N. Kolonel, and B. E. Henderson
Risk Factors for Renal Cell Cancer: The Multiethnic Cohort
Am. J. Epidemiol., October 15, 2007; 166(8): 932 - 940.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. Ansary-Moghaddam, R. Huxley, F. Barzi, C. Lawes, T. Ohkubo, X. Fang, S. H. Jee, M. Woodward, and Asia Pacific Cohort Studies Collaboration
The Effect of Modifiable Risk Factors on Pancreatic Cancer Mortality in Populations of the Asia-Pacific Region
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2435 - 2440.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Rocken, U. Lendeckel, J. Dierkes, S. Westphal, S. Carl-McGrath, B. Peters, S. Kruger, P. Malfertheiner, A. Roessner, and M. P.A. Ebert
The Number of Lymph Node Metastases in Gastric Cancer Correlates with the Angiotensin I-Converting Enzyme Gene Insertion/Deletion Polymorphism
Clin. Cancer Res., April 1, 2005; 11(7): 2526 - 2530.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. P. W. A. Houben, W. J. Louwman, C. C. Tijssen, J. L. J. M. Teepen, C. M. van Duijn, and J. W. W. Coebergh
Hypertension as a risk factor for glioma? Evidence from a population-based study of comorbidity in glioma patients
Ann. Onc., August 1, 2004; 15(8): 1256 - 1260.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
I. Goldenberg, M. Shechter, S. Matetzky, M. Jonas, M. Adam, H. Pres, D. Elian, O. Agranat, E. Schwammenthal, and V. Guetta
Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: A randomized controlled trial and review of the current literature
Eur. Heart J., February 1, 2004; 25(3): 212 - 218.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Grossman, E
Right arrow Articles by Goldbourt, U
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grossman, E
Right arrow Articles by Goldbourt, U
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?